Can you explain what you mean by subtyping and if/how it negates the usefulness of repurposing (if that’s what you meant to say). Wouldn’t subtyping complement a drug repurposing screen by allowing the scientist to test compounds against a subset of a disease?
And drug repurposing is also used for conditions with no known molecular basis like autism. You’re not suggesting its usefulness is limited in those cases right?
Sure. There are studies like BEAT-AML which tests selected drugs’ responses on primary AML material. So, not on a cell-line but on true patient data. Combining this information with molecular measurements, you can actually say something about which drugs would be useful for a subset of the patients.
However, this is still not how you treat a patient. There are standard practices in the clinic. Usually the first line treatment is induction chemo with hypomethylating agents (except elderly who might not be eligible for such a treatment). Otherwise the options are still very limited, the “best” drug in the field so far is a drug called Venetoclax, but more things are coming up such as immuno-therapy etc. It’s a very complex domain, so drug repurposing on an AML cell line is not a wow moment for me.
It’s not discriminatory at all! Or even the point OP is trying to make. Taking a significant number of jobs and outsourcing them overnight will quickly result in running out the talent pool in said country. It’s shortsighted and stupid because it assumes that there is an army of developers just sitting around standing by waiting for the next western tech company to give them high paying remote jobs. A large portion of that talent pool is already reserved by the biggest corporations.
Build up to it and foster growth in your overseas teams and you’ll do well. Thinking you can transform your department overnight _is_ a great way to boost your share price, cash out on a fat payday and walk away before your product quality tanks.
Absolutely not true in my experience. MySQL has its share of issues (all DBs do) but it is rock-solid when using the correct engine (InnoDB for most cases, RocksDB for high-throughput writes, Memory for caching). MySQL is very hard to beat for very high-volume OLTP workloads, both reads and writes. Its replication systems were years ahead of other systems (SQL Server, Postgres, SQLite doesn't have replication). DuckDB AFAIK is OLAP and they don't compete in the same space. Every DB system has "the things its good at" and MySQL really shines at very high-volume OLTP spread across partitions.
Or scalpers won’t be dissuaded and street price for a 5090 will be $3200 or more. $1500 was already an insane price tag for scalpers to pay but they did it anyways.
The scalpers are trying to arbitrage the difference in price between the prices bought directly from suppliers and those on the open secondary market.
increasing the retail price doesn't increase the price on the secondary market, it just lowers the margin of scalpers.
They’re claiming DLSS4 (only available on their new cards) fixes a lot of these issues. But we’ll have to wait for the cards to get in the hands of reviewers before we’ll know for sure. I'm still pretty skeptical.
That said, if you read between the lines, it looks like the new 5090 is about ~40% faster than the 4090 at rasterisation. That’s a solid inter generational improvement.
> In practice abolishing Chevron deference mostly means rules will follow the politics of judges rather than the current administration. TBH I think this rule is far enough from the culture war that it will probably stand anyway. Unless the NYT happens to buy the judges a lot of vacations...
I want to agree with you but the vote was split down party lines completely with 2 dissenters being republican.
And drug repurposing is also used for conditions with no known molecular basis like autism. You’re not suggesting its usefulness is limited in those cases right?